|
|
 |
|
Publications
Click
here for a full listing of DART publications.
DART Trial Team. Routine versus clinically
driven laboratory monitoring of HIV antiretroviral therapy in Africa
(DART): a randomised non-inferiority trial. Lancet 2010; 375:123-31.
Kityo
C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R,
Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; DART Trial
Team. Pharmacokinetics of lopinavir-ritonavir with and without
nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected
adults. Antimicrobial Agents & Chemotherapy 2010 Jul; 54(7):2965-73. Epub
2010 Apr 26
Walker AS, Ford D, Gilks C, Munderi P, Ssali
F, Reid A, Katabira E, Grosskurth H, Mugyenyi P, Hakim J, Darbyshire
JH, Gibb DM, Babiker AG. Daily cotrimoxazole prophylaxis in severely
immunosuppressed adults in Africa started on combination antiretroviral
therapy. Lancet
2010 Apr 10; 375(9722):1278-86.
Epub 2010 Mar 27
Munderi P, Walker AS, Kityo C, Babiker AG,
Ssali F, Reid A, Darbyshire JH, Grosskurth H, P Mugyenyi, Gibb DM,
Gilks CF on behalf of the DART/NORA trial teams.
Nevirapine/zidovudine/lamivudine has superior immunological and
virological responses not reflected in clinical outcomes in a 48 week
randomised comparison with abacavir/zidovudine/lamivudine in
HIV-infected Ugandan adults with low CD4 counts. HIV Medicine 2010
May; 11(5):334-44.
Epub 2010 Feb 3
McCormick A, Goodall R, Joyce A, Walker AS,
Ndembi N, Chirara M, Kityo C, Yirrell D, Gilks C, Pillay D, on behalf
of the DART Virology Group and Trial Team.. Lack of minority K65R
resistant viral populations detected after repeated treatment
interruptions of Tenofovir/Zidovudine and Lamivudine in a
resource-limited setting. JAIDS
2010 Jun; 54(2):215-6
Ndembi N, Kaleebu P, Goodall RL, Dunn DT
McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C,
Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Pillay D on
behalf of the DART Virology Group and Trial Team. Viral rebound and
emergence of drug resistance in the absence of viral load testing: a
randomised comparison between zidovudine-lamivudine plus nevirapine and
zidovudine-lamivudine plus abacavir. JID 2010; 201:106-13.
Nyanzi Wakholi B, Medina Lara A, Munderi P,
Gilks C, Grosskurth H on behalf of the DART trial team. The role of HIV
testing, counseling, and treatment in coping with HIV/AIDS in Uganda: A
qualitative analysis. AIDS Care Journal 2009; 21:903-8.
Stöhr
W, Walker AS, Munderi P, Tugume S, Gilks CF, Darbyshire JH, Hakim J on
behalf of the DART trial. Estimating glomerular filtration rate in
HIV-infected adults in Africa: comparison of Cockcroft-Gault and MDRD
formulae. Antiviral
Therapy 2008;13(6):761-70.
Muyingo
SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, Levin J,
Katabira E, Gilks C, Todd J, and the DART Trial
Team *. Patterns of individual and population-level adherence
to ART and risk factors for poor adherence in the first year of the
DART trial in Uganda and Zimbabwe. JAIDS
2008;48(4):468-475
Reid
AJ, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P,
Kambugu A, Gilks CF, Mugyenyi P, Munderi P, Hakim J, Gibb DM on behalf
of the DART Trial. Severe renal dysfunction and risk factors associated
with renal impairment in adults with HIV infection in Africa initiating
antiretroviral therapy. CID 2008; 46:1271–1281
DART
Trial Team. 24 Week Safety and Tolerability of Nevirapine Versus
Abacavir in Combination with Zidovudine/Lamivudine as First-Line
Antiretroviral Therapy: A Randomised Double-Blind Trial (NORA). TIMH 13
(1), 6-16doi10.111/j.1365-3156.2007.01973.x
DART
Trial Team. Fixed Duration Interruptions are Inferior to Continuous
Treatment in African Adults Starting Therapy with CD4<200
Cells/µL. AIDS. 2008;22(2):237-47.
Medina
Lara A, Nyanzi Wakholi B, Kasirye A, Munderi P, Watera C, Lalloo DG,
Haycox A, Gilks CF and Grosskurth H on behalf of the DART trial team.
Utility Assessment of HIV/AIDS Related Health States In HIV Infected
Ugandans. AIDS 2008;22 Suppl 1:S123-30
Kikaire
B, Khoo S, Walker AS, Ssali F, Munderi P, Namale L, Reid A, Gibb DM,
Mugyenyi P, and Grosskurth H on behalf of the DART Trial team.
Nevirapine clearance from plasma in African adults stopping therapy - a
pharmacokinetic substudy. AIDS 2007;21:733-7
Ssali
F, Stöhr W, Munderi P, Reid A, Walker AS, Gibb DM, Mugyenyi P,
Kityo C, Grosskurth H, Hakim J, Darbyshire JH, Gilks CF and the DART
Trial Team. Incidence and Predictors of Severe Anaemia with
Zidovudine-containing Regimens in Africa Adults with HIV Infection
within the DART Trial. Antiviral Therapy 2006; 11:741-9.
DART
Virology Group and Trial Team. Virological response to a triple
nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected
adults in Africa. AIDS 2006; 20:1391-9
|
Oral presentations
 |
Risk
of WHO 4 events and death by current CD4 on ART in the DART trial: the
impact of CD4-dependent reporting bias
17th Conference on Retroviruses and Opportunistic Infections, 16-19
February 2010, San Francisco USA |
|
Immune
restoration over 5 years on ART among patients initiating treatment
with advanced immune deficiency in the DART trial in Uganda and Zimbabwe
17th Conference on Retroviruses and Opportunistic Infections, 16-19
February 2010, San Francisco USA |
|
Design
of the DART trial and key substudy
results
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
Impact
of routine laboratory monitoring
over 5 years after ART initiation, the DART Trial final results
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
Cost
effectiveness analysis of routine
laboratory or clinically driven strategies - DART
trial
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
What
have we learnt from the DART trial?
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
DART LPV
NNRTI PK
Ninth International Congress on Drug Therapy in HIV Infection 9-13
November 2008 Glasgow, UK
|
|
Discordance
between virological/immunological and clinical outcomes:
NORA efficacy 4th IAS Conference on HIV Pathogenesis, Treatment and
Prevention, Sydney, 22-25 July 2007
|
|
Adherence to ART
in DART trial subjects
1st Interest Workshop on HIV Treatment, Pathogenesis and Prevention
Research in Resource-poor Settings, Kampala, 30 May-2 June, 2007
|
|
STI
acceptability in DART
8th International Congress on Drug Therapy in HIV Infection, Glasgow,
12-16 November 2006
|
|
Structured
Treatment Interruptions (STIs) in DART
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Mortality rates
and causes of death pre- and post-ART
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Glomerular
dysfunction following initiation of ART
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Pharmacokinetics
of Nevirapine following interruption
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Safety of
Nevirapine compared to Abacavir, both with Combivir: the NORA trial,
13th Conference on Retroviruses and
Opportunistic Infections, Denver, 5-8 February 2006
|
|
48 week
virological response to Combivir+Tenofovir,
3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro,
24-27 July 2005
|
|
24 week
virological response to Combivir+Tenofovir,
12th Conference on Retroviruses and Opportunistic Infections, Boston,
22-25 February 2005
|
|
Severe
anaemia in the DART trial,
12th Conference on Retroviruses and Opportunistic Infections, Boston,
22-25 February 2005
|
|
Entebbe
Cohort survival,
XV International AIDS Conference, Bangkok, 11-16 July 2004
|
|
DART
trial update,
13th International Conference on HIV/AIDS and Sexually Transmitted
Infections in Africa, Nairobi, 21-26 September 2003
|
Posters
|
J.K.
Kayondo, N. Ndembi, P.A. Cane, C Kityo, M Chirara, R Goodall, D Dunn,
P. Kaleebu, D. Pillay, and J.L. Mbisa. Different evolution of
resistance uncovered by single genome sequencing (SGS) analysis of
patients with long term virological failure during continuous or
interrupted therapy. Abstract 113, International HIV and
Hepatitis Virus Drug Resistance Workshop and Curative Strategies, June
8-12 2010, Dubrovnik, Croatia & Antiviral Therapy 2010; 15
Suppl 2:A142. |
|
Pregnancy
rates and outcomes among women on
triple-drug ART
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
Glomerular
dysfunction and associated risk
factors
5th IAS
Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July
2009, Cape Town, South Africa
|
|
Effect
of WHO stage 3/4 events after ART
initiation on survival
5th IAS Conference on HIV Pathogenesis,
Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa
|
|
Difficulties
in assigning AIDS endpoints in
clinical trials in resource limited
settings
5th IAS Conference on HIV Pathogenesis,
Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
Impact of
daily cotrimoxazole prophylaxis
in severely immunosuppressed adults
5th IAS Conference on HIV Pathogenesis,
Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa
|
|
Long-term
randomised comparison of clinical
outcomes following ART initiation :
NORA
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
Epidemiology
of malaria in HIV infected
patients on ART in Uganda: a prospective cohort study
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22
July 2009, Cape Town, South Africa
|
|
DART NORA VIROLOGY - Phenotypic data
XVIII International HIV Drug Resistance Workshop, 9-13 June 2009, Fort
Myers, Florida
|
|
DART NORA VIROLOGY - Prevalence and in vitro
characteristics of (RT) N348I
16th Conference on Retroviruses and Opportunistic Infections, 8-11
February 2009, Palais des Congrés de Montréal,
Montréal Canada
|
|
DART VIROLOGY - STI
16th Conference on Retroviruses and Opportunistic Infections, 8-11
February 2009, Palais des Congrés de Montréal,
Montréal Canada
|
|
IMPACT
OF KALETRA BASED SECOND-LINE ART REGIMEN
XVII International AIDS Conference, Mexico City, 3-8 August 2008
|
|
DART
NORA VIROLOGY
15th Conference on Retroviruses and Opportunistic Infections, Boston,
USA, 5-8 February 2008
|
|
RESPONSES
TO SECONDLINE
15th Conference on Retroviruses and Opportunistic Infections, Boston,
USA, 5-8 February 2008
|
|
COTRIMOXAZOLE
PROPHYLAXIS IN DART
15th Conference on Retroviruses and Opportunistic Infections, Boston,
USA, 5-8 February 2008
|
| |
Does
Cotrimoxazole Prophylaxis Improve Outcomes after ART Initiation in
HIV-infected African Adults
15th Conference on Retroviruses and Opportunistic Infections, 5-8
February 2008, Boston
|
| |
Immunological
Response to Boosted PI-Containing Second Line ART
15th Conference on Retroviruses and Opportunistic Infections, 5-8
February 2008, Boston
|
| |
The
relationship between viral load and emergence of drug resistance
15th Conference on Retroviruses and Opportunistic Infections, 5-8
February 2008, Boston
|
| |
Virological
and clinical efficacy in the NORA substudy of DART,
14th Conference on Retroviruses and Opportunistic Infections, Los
Angeles, 25-28 February 2007
|
| |
Pregnancy
and outcome in DART,
14th Conference on Retroviruses and Opportunistic Infections, Los
Angeles, 25-28 February 2007
|
| |
48 week
resistance on Combivir+Tenofovir,
14th Conference on Retroviruses and Opportunistic Infections, Los
Angeles, 25-28 February 2007
|
|
STI
acceptability in DART
8th International Congress on Drug Therapy in HIV Infection, Glasgow,
12-16 November 2006
|
|
Qualitative
Quality of Life Changes
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Quantitative
Quality of Life Changes
XVI International AIDS Conference, Toronto, 13-18 August 2006
|
|
Immunological
changes on STIs
AIDS Vaccine 2006 Conference, Amsterdam, 29 August - 1 September 2006
|
|
48 week
virological response to Combivir+Tenofovir,
3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro,
24-27 July 2005
|
|
DART
trial update,
XV International AIDS Conference, Bangkok, 11-16 July 2004
|
|
CD4 response in
the DART trial,
11th Conference on Retroviruses and Opportunistic Infections, San
Francisco, 8-11 February 2004
|
|
|